Non-small Cell Lung Cancer Drugs Market, Global Outlook and Forecast 2024-2030

22 March 2024
Life Sciences
62 Pages
Report code : PMR-7856562

4.7

(158)

Download Free PDF sample

Non-small Cell Lung Cancer Drugs Market

Download FREE Report Sample

Download Free sample

The global Non-small Cell Lung Cancer Drugs market was valued at US$ 31,614.8 million in 2023 and is projected to reach US$ 68,888.6 million by 2029, at a CAGR of 9.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
Non-small Cell Lung Cancer Drugs Market aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Drugs. Non-small Cell Lung Cancer Drugs Market contains market size and forecasts of Non-small Cell Lung Cancer Drugs in global, including the following market information:

Global Non-small Cell Lung Cancer Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2023 (%)

The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing.
We surveyed the Non-small Cell Lung Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-small Cell Lung Cancer Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Type, 2023 (%)

Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other

Global Non-small Cell Lung Cancer Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Application, 2023 (%)

Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma

Global Non-small Cell Lung Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, By Region and Country, 2023 (%)

North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

Key companies Non-small Cell Lung Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-small Cell Lung Cancer Drugs revenues share in global market, 2023 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.

Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-small Cell Lung Cancer Drugs, market overview.
Chapter 2: Global Non-small Cell Lung Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-small Cell Lung Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

CHECK TODAYS BEST PRICE

Request
Chapter Price

Download
Free Sample

SECURITY ASSURED payment image

Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research

Frequently Asked Questions ?

User License

A license granted to one user.
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
Multi user License
A license granted to multiple users.
Site License
A license granted to a single business site/establishment.
Corporate License, Global License
A license granted to all employees within organisation access to the product.

Delivery Time

Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

WHY CHOOSE US

Proactive We manage our resources 24/7 to identify issues and address them before they become problems
Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach 6 Major regions and 40+ countries level analysis accomplished
Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery